Gligem-MF3 Forte Tablet SR is a combination oral hypoglycemic agent containing Glimepiride 3mg and Metformin 1000mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity without causing significant hypoglycemia. The sustained-release formulation ensures a gradual release of active ingredients, minimizing gastrointestinal side effects commonly associated with Metformin and improving patient compliance through once-daily dosing. Gligem-MF3 Forte is indicated for use in patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve target glycemic levels. It is essential to monitor blood glucose regularly and adjust dosages accordingly to prevent hypoglycemia. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. This combination therapy offers a synergistic approach, addressing multiple pathophysiological defects in type 2 diabetes, thereby improving overall glycemic control and reducing the risk of diabetes-related complications.